Ollonen, Teemu
Kurkela, Margareta
Laitakari, Anna
Sakko, Samuli
Koivisto, Henna
Myllyharju, Johanna
Tanila, Heikki
Serpi, Raisa
Koivunen, Peppi http://orcid.org/0000-0002-2827-8229
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (266719, 308009, 296498, 251314)
Academy of Finland (284605)
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
Biocenter Finland
University of Oulu including Oulu University Hospital
Article History
Received: 5 January 2022
Revised: 27 June 2022
Accepted: 29 June 2022
First Online: 19 July 2022
Declarations
:
: Financial interests: JMy owns equity in FibroGen, Inc., which develops HIF-P4H inhibitors as therapeutics and supports research in JMy laboratory. The other authors have no relevant financial or non-financial interests to disclose.
: All animal experiments were performed according to protocols approved by the Animal Experiment Board of Finland (ESAVI-8179-04.10.07-2017).